Biomea Fusion completes enrollment in COVALENT-211 Phase II icovamenib trial in insulin-deficient type 2 diabetes
BMEA•Second Phase II study remains enrolling
A second Phase II study, COVALENT-212 in patients not controlled on GLP-1-based therapy, remains enrolling with data expected in Q2 2027.
Phase II enrollment completed in COVALENT-211
Biomea Fusion completed enrollment in the Phase II COVALENT-211 trial of icovamenib in insulin-deficient type 2 diabetes.
Topline results for the 26-week primary endpoint will be presented in Q1 2027; no new efficacy results were reported.
The study is designed to test whether a short treatment course can deliver durable blood-sugar control after dosing ends.
Enrollment reached 64 participants across 18 sites, with patients randomized 2:1 to icovamenib or placebo.
